Skip to main content
. 2020 Mar 12;10(3):106. doi: 10.3390/metabo10030106

Figure 7.

Figure 7

Future antifungal therapy may benefit from these substances including tetrazoles VT-1129 (A), VT-1161 (B), VT-1598 (C); triazole PC1244 (D); echinocandin rezafungin (E); triterpenoid Ibrexafungerp (F); inositol transferase inhibitor Fosmanogepix (G); dihydroorotate dehydrogenase inhibitor Olorofim (H); histone deacetylase inhibitor MGCD290 (I); monoterpenoids citronellal (J) and perillaldehyde (K); brominated acylhydrazones BHBM (L) and its derivative D13 (M); triterpenoid celastrol (N); and hydroxamate type siderophore VL-2397 (O).